A new gene for Fahr's syndrome-PDGF-B

Medicinal pteridophytes: ethnopharmacological, phytochemical, and clinical attributes

Background

Almost from the very beginning of human existence, man has been interacting with plants. Throughout human history, plants have provided humans with basic needs such as sustenance, firewood, livestock feed, and wood. The world has approximately 3 million vascular plants. The treatment of primary health problems is provided primarily by traditional medicines by around 80% of the world's population. Compared to other vascular plants, pteridophytes remain underexplored in ethnobotanical aspects, despite being regarded as a valuable component of healthcare for centuries. As an alternative medicine, pteridophytes are being investigated for their pharmacological activity. Almost 2000 years ago, humans were exploring and using plant species from this lineage because of its beneficial properties since pteridophytes were the first vascular plants.

Main body of the abstract

All popular search engines such as PubMed, Google Scholar, ScienceDirect, and Scopus were searched to retrieve the relevant literature using various search strings relevant to the topic. Pteridophytes belonging to thirty different families have been documented as medicinal plants. For instance, Selaginella sp. has been demonstrated to have numerous therapeutic properties, including antioxidative, inflammation-reducing, anti-carcinogenic, diabetes-fighting, virucidal, antibacterial, and anti-senile dementia effects. In addition, clinical trials and studies performed on pteridophytes and derived compounds are also discussed in details.

Short conclusion

This review offers a compilation of therapeutically valuable pteridophytes utilized by local ethnic groups, as well as the public.

Graphical Abstract

Deconstructing Fahr's disease/syndrome of brain calcification in the era of new genes

INTRODUCTION

There are now a number genes, known to be associated with familial primary brain calcification (PFBC), causing the so called 'Fahr's' disease or syndrome. These are SCL20A2, PDGFB, PDGFRB and XPR1. In this systematic review, we analyse the clinical and radiological features reported in genetically confirmed cases with PFBC. We have additionally reviewed pseudohypoparathyroidism which is a close differential diagnosis of PFBC in clinical presentation and is also genetically determined.

METHODS

We performed a Medline search, from 1st Jan 2012 through to 7th November 2016, for publications with confirmed mutations of SCL20A2, PDGFB, PDGFRB, and XPR1 and found twenty papers with 137 eligible cases. A second search was done for publications of cases with Pseudohypoparathyroidism or pseudopseudohypoparathyroidism, and found 18 publications with 20 eligible cases.

RESULTS

SLC20A2 was the most common gene involved with 75 out of 137 cases included with PFBC (55%) followed by PDGFB (31%) and PDGFRB (11%). Statistically significant correlation was found between the presence of parkinsonism with SLC20A2 mutations, headache in PDGFB and generalised tonic-clonic seizures in patients with pseudohypoparathyroidism.

CONCLUSION

We combine statistical analysis and clinical inference to suggest a diagnostic algorithm based on the observations in this study to help with investigation of a patient with neurological features and brain calcification.